COMP <GO>
CHRS vs TARA // REVENUE GROWTH (YOY)
Coherus Oncology Inc. (NASDAQ) VS. Protara Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: CHRS 1
— TARA 3
■ METRIC PARITY
LAST: $0.83 (-7.60%) • MKT CAP: $138.8M
revenue-growth
—
LAST: $2.48 (-1.59%) • MKT CAP: $148.9M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CHRS VS. TARA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CHRS | TARA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -34.70% | -0.30 | TARA | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 2/9 | +1.00 | CHRS | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.3 | 38.3 | -4.06 | TARA | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $138.8M | $148.9M | -$10.1M | TARA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CHRS REV | TARA REV | CHRS GROSS % | TARA GROSS % | CHRS FCF | TARA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $0 | — | — | -$138.5M | -$56.5M |
| FY 2024 | $0 | $0 | — | — | -$20.4M | -$35.9M |
| FY 2023 | $0 | $0 | — | — | -$174.9M | -$37.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CHRS // BETA —
TARA // BETA —